Fleeing to France to afford life-saving meds. Sanofi's Dupixent and the pricing cliff.
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Fleeing to France to afford life-saving meds. Sanofi's Dupixent and the pricing cliff.
-
Narrated by:
-
By:
Summary
As a health care provider, and former pharmaceutical industry researcher and executive, I explore in this podcast the stark contrast between international healthcare costs and the expensive medical landscape in the United States. Helping me is AI which creates a two-way narrative based on my research and personal viewpoint.
One narrative follows an American woman who moved to France, where her annual asthma treatment costs dropped from $36,000 to $3,000, highlighting the benefits of universal healthcare and stricter pharmaceutical regulations. Corporate filings from Sanofi further reveal the significant market risks and pricing pressures pharmaceutical giants face due to legislative shifts like the Inflation Reduction Act. Additionally, the texts note that biologic therapies for conditions like asthma and COPD remain a primary driver of high costs in the American system. These sources collectively suggest that medical emigration is becoming a viable solution for citizens burdened by rising drug prices and toxic food standards. Overall, the collection serves as a comparative study of how regulatory frameworks and government drug-pricing policies directly influence patient well-being and corporate strategy.